CytoSorbents Corporation, a  critical care immunotherapy company, has been granted Emergency Use Authorization (EUA)  by the FDA for CytoSorb for use in patients with COVID-19 infection. CytoSorb is a blood purification technology to treat cytokine storm and deadly inflammation in critically-ill patients. Under the EUA, CytoSorb can be used in patients 18 years of age or older, with confirmed COVID-19 who are admitted to the intensive care unit (ICU) with respiratory failure, early acute lung ...